[ 1 ] Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, et al. Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: a hint for COVID-19 treatment. Engineering. In press.

[ 2 ] Pham T, Rubenfeld GD. Fifty years of research in ARDS. The epidemiology of acute respiratory distress syndrome. A 50th birthday review. Am J Respir Crit Care Med 2017;195(7):860–70. link1

[ 3 ] Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers 2019;5(1):19. link1

[ 4 ] Lew TW, Kwek TK, Tai D, Earnest A, Loo S, Singh K, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 2003;290(3):374–80. link1

[ 5 ] Cockrell AS, Yount BL, Scobey T, Jensen K, Douglas M, Beall A, et al. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat Microbiol 2016;2(2):16226. link1

[ 6 ] Chen J, Wu J, Hao S, Yang M, Lu X, Chen X, et al. Long term outcomes in survivors of epidemic influenza A (H7N9) virus infection. Sci Rep 2017;7 (1):17275. link1

[ 7 ] Ke C, Mok CKP, Zhu W, Zhou H, He J, Guan W, et al. Human infection with highly pathogenic avian influenza A (H7N9) virus, China. Emerg Infect Dis 2017;23(8):1332–40. link1

[ 8 ] Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Eng J Med 2013;368(20):1888–97. link1

[ 9 ] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395 (10223):497–506. link1

[10] Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017;39(5):529–39. link1

[11] Lamichhane PP, Samarasinghe AE. The role of innate leukocytes during influenza virus infection. Clin Dev Immunol 2019;2019:8028725. link1

[12] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20. link1

[13] Yoon YM, Han YS, Yun CW, Lee JH, Kim R, Lee SH. Pioglitazone protects mesenchymal stem cells against P-cresol-induced mitochondrial dysfunction via up-regulation of PINK-1. Int J Mol Sci 2018;19(10):2898. link1

[14] Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007;25(11):2739–49. link1

[15] Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418(6893):41–9. link1

[16] Antebi B, Walker KP, Mohammadipoor A, Rodriguez LA, Montgomery RK, Batchinsky AI, et al. The effect of acute respiratory distress syndrome on bone marrow-derived mesenchymal stem cells. Stem cell Res Ther 2018;9 (1):251. link1

[17] Liang J, Li X, Zhang H, Wang D, Feng X, Wang H, et al. Allogeneic mesenchymal stem cells transplantation in patients with refractory RA. Clin Rheumatol 2012;31(1):157–61. link1

[18] Pati S, Gerber MH, Menge TD, Wataha KA, Zhao Y, Baumgartner JA, et al. Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock. PLoS ONE 2011;6(9):e25171. link1

[19] Goolaerts A, Pellan-Randrianarison N, Larghero J, Vanneaux V, Uzunhan Y, Gille T, et al. Conditioned media from mesenchymal stromal cells restore sodium transport and preserve epithelial permeability in an in vitro model of acute alveolar injury. Am J Physiol Lung Cell Mol Physiol 2014;306(11):L975–85. link1

[20] Walter J, Ware LB, Matthay MA. Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet Respir Med 2014;2 (12):1016–26. link1

[21] Kim HJ, Park JS. Usage of human mesenchymal stem cells in cell-based therapy: advantages and disadvantages. Dev Reprod 2017;21(1):1–10. link1

[22] Keener A. The genetic shortcut to antibody drugs. Nature 2018;564(7735): S16–7. link1

[23] Braun J, Baraliakos X, Westhoff T. Nonsteroidal anti-inflammatory drugs and cardiovascular risk—a matter of indication. Semin Arthritis Rheu 2020;50 (2):285–8. link1

[24] Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2 mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 2020;11(2):216–28. link1